{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-119230","form_type":"8-K/A","ticker":"STAA","cik":"0000718937","company_name":"STAAR SURGICAL CO","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.899378+00:00","generated_at":"2026-05-30T07:47:48.606599+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"STAAR Surgical reports Q3 net sales up 10% to $88.6M; revises 2024 regional growth assumptions","bullets":["Net income of $10.0M ($0.20 EPS) vs $4.8M ($0.10 EPS) a year ago; adjusted EBITDA $16.2M.","ICL sales $89.1M, up 10%; gross margin 77.3% vs 79.2% on lower production absorption.","FY 2024 net sales outlook maintained at $340-345M; adjusted EBITDA ~$42M.","Americas EVO ICL growth revised to 17% (was 15%); U.S. to 20% (was 25%); EMEA to 10% (was 6%).","APAC growth cut to 5% (was 7%); China growth slashed to ~2% (was 10%); other APAC now 10-20% (was flat)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-119230","json":"https://secwatch.observer/filing/0000950170-24-119230.json","markdown":"https://secwatch.observer/filing/0000950170-24-119230.md","text":"https://secwatch.observer/filing/0000950170-24-119230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/718937/000095017024119230/0000950170-24-119230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/718937/000095017024119230/staa-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:47:48.606599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}